Results 161 to 170 of about 80,978 (300)

Preliminary results of a single, easy-to-use device for multimodal detection of intervals associated with heart failure decompensation. [PDF]

open access: yesEur Heart J Digit Health
Sánchez-Ortiz D   +11 more
europepmc   +1 more source

SURGELLA: A Scoping Review of Impella‐Assisted Hemodynamic Support in High‐Risk Non‐Cardiac Surgery

open access: yesArtificial Organs, EarlyView.
In selected patients with severe LV dysfunction, Impella‐supported non‐cardiac surgery may provide a temporary hemodynamic bridge to otherwise prohibitive procedures. Published evidence remains limited to a small number of highly selected cases, supporting technical feasibility rather than comparative benefit or generalizable safety.
Hussein Elghazaly   +6 more
wiley   +1 more source

Clinical outcomes of the PAUL® glaucoma implant for secondary glaucoma

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose Secondary glaucoma encompasses a broad spectrum of disease entities arising from diverse ocular pathologies and is often refractory to conventional treatment. Glaucoma drainage devices (GDDs) have therefore become an important surgical option.
Carolin Deubel   +7 more
wiley   +1 more source

Thyroid disorders in heart failure and its effects on decompensation

open access: yes, 2009
Tıp Fakültesi, Kardiyoloji Ana Bilim DalıSol kalp yetersizliği sık görülen bir sendromdur. Populasyonun yaşam süresinin uzaması, akut koroner sendromlar sonrasında hayatta kalma oranın artması ve etiyolojik risk faktörlerinin görülme sıklığının artması ...
Dizman, Rafet
core  

Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Summary of a multicentre TriNetX study evaluating outcomes after percutaneous coronary intervention (PCI) in patients with cirrhosis. Cirrhosis was associated with higher 1‐year gastrointestinal bleeding and mortality, especially with decompensated disease.
Dhir Gala   +13 more
wiley   +1 more source

Review Article: Fibrosis Reversal in Metabolic Dysfunction‐Associated Steatohepatitis—The Promise of Emerging Therapeutics

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Metabolic dysfunction‐associated steatohepatitis is the second commonest US indication for liver transplantation but remains largely undiagnosed and untreated. Fibrosis stage is the strongest predictor of major adverse liver outcomes, with decompensation rates and transplant‐free survival diverging sharply between F3 and F4, while cardiovascular ...
Malek Ayoub   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy